State

US Virgin Islands product recalls

73,824 recalls have nationwide distribution and so reach US Virgin Islands. 178 additional recalls listed US Virgin Islands specifically in their distribution scope.

What the numbers show

Total: 178
Critical: 12
Severe: 39
Most recent: 2026-10-21

Of the 178 recalls naming US Virgin Islands we have scored against our rubric, 12 (7%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 39 (22%) are Severe.

Which agencies issued them

These figures cover only the 178 recalls whose distribution notice names US Virgin Islands specifically. The 73,824 nationwide recalls listed below reach every state, so counting them here would make every state page show the same numbers.

54351–54375 of 74002

SevereFDA (Drugs)·D-599-2015·2015-04-29
Attix Pharmaceuticals Recalls Colchicine API Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling colchicine active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging. The product was distributed to compounding pharmacies and research organizations.
Product
Colchicine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-536-2015·2015-04-29
Attix Pharmaceuticals Recalls Benazepril API Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Benazepril active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Benazepril active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-539-2015·2015-04-29
Attix Pharmaceuticals Recalls Benztropine Mesylate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Benztropine Mesylate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Benztropine Mesylate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-552-2015·2015-04-29
Attix Pharmaceuticals Recalls Bupivacaine HCl Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Bupivacaine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Bupivacaine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-857-2015·2015-04-29
Prednisolone API Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Prednisolone Anhydrous Micronized API due to potential penicillin cross-contamination from inadequate facility separation.
Product
Prednisolone Anhydrous Micronized active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-851-2015·2015-04-29
Attix Pharmaceuticals Recalls Potassium Phosphate Monobasic Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling all lots of Potassium Phosphate Monobasic distributed between January 2012 and February 2015 due to potential penicillin cross-contamination.
Product
Potassium Phosphate Monobasic pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-569-2015·2015-04-29
Attix Pharmaceuticals Recalls Cefpodoxime Proxetil Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Cefpodoxime Proxetil active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Cefpodoxime Proxetil active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-903-2015·2015-04-29
Attix Pharmaceuticals Recalls Spectinomycin Sulfate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Spectinomycin Sulfate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Spectinomycin Sulfate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-642-2015·2015-04-29
Attix Pharmaceuticals Recalls Doxycycline Hyclate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Doxycycline Hyclate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Doxycycline Hyclate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-755-2015·2015-04-29
Attix Pharmaceuticals Recalls Levocetirizine Dihydrochloride Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Levocetirizine Dihydrochloride active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Levocetirizine Dihydrochloride active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-838-2015·2015-04-29
Attix Pharmaceuticals Recalls Pheniramine Maleate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Pheniramine Maleate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Pheniramine Maleate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-684-2015·2015-04-29
Fluoxetine Hydrochloride Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Fluoxetine Hydrochloride active pharmaceutical ingredient due to potential penicillin cross contamination during repackaging.
Product
Fluoxetine Hydrochloride active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-752-2015·2015-04-29
Attix Pharmaceuticals Recalls Leucovorin Calcium Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Leucovorin Calcium active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Leucovorin Calcium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-726-2015·2015-04-29
Attix Pharmaceuticals Recalls Hyoscyamine Sulfate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Hyoscyamine Sulfate Dihydrate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Hyoscyamine Sulfate Dihydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-626-2015·2015-04-29
Attix Pharmaceuticals Recalls Dexmedetomidine HCI Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Dexmedetomidine HCI active pharmaceutical ingredient due to potential penicillin cross-contamination from repackaging in a shared facility.
Product
Dexmedetomidine HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-635-2015·2015-04-29
Attix Pharmaceuticals Recalls Dobutamine Hydrochloride Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Dobutamine Hydrochloride active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Dobutamine Hydrochloride active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-557-2015·2015-04-29
Attix Pharmaceuticals Recalls Calcium Sulfate Hemihydrate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Calcium Sulfate Hemihydrate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Calcium Sulfate Hemihydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-849-2015·2015-04-29
Attix Pharmaceuticals Recalls Potassium Acetate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling all lots of Potassium Acetate active pharmaceutical ingredient distributed between January 5, 2012, and February 12, 2015, due to a risk of penicillin cross-contamination.
Product
Potassium Acetate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-934-2015·2015-04-29
Attix Pharmaceuticals Recalls Tolfenamic Acid Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Tolfenamic Acid active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Tolfenamic Acid active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-563-2015·2015-04-29
Attix Pharmaceuticals Recalls Carboxymethyl Cellulose Sodium Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Carboxymethyl Cellulose Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Carboxymethyl Cellulose Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-491-2015·2015-04-29
Attix Pharmaceuticals Recalls 5-Aminolevulinic Acid Hydrochloride Due to Penicillin Cross-Contamination
Attix Pharmaceuticals is recalling 5-Aminolevulinic Acid Hydrochloride active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
5-Aminolevulinic Acid Hydrochloride active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-736-2015·2015-04-29
Attix Pharmaceuticals Recalls Isoproterenol Hydrochloride Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Isoproterenol Hydrochloride active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Isoproterenol Hydrochloride active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-747-2015·2015-04-29
Attix Pharmaceuticals Recalls Lamotrigine Ingredient Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling lamotrigine active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Lamotrigine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-879-2015·2015-04-29
Ribavirin Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Ribavirin active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Ribavirin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-549-2015·2015-04-29
Attix Pharmaceuticals Recalls Bromocriptine Mesylate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Bromocriptine Mesylate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Bromocriptine Mesylate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide